Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Denver, CO
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Tampa, FL
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Chicago, IL
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Normal, IL
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Normal, IL
Click here to add this to my saved trials
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Ypsilanti, MI
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Minneapolis, MN
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Saint Louis, MO
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Rochester, NY
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Gahanna, OH
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Gahanna, OH
Click here to add this to my saved trials
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Portland, OR
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Research Site
mi
from
Philadelphia, PA
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Research Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Charleston, SC
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
North Charleston, SC
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
North Charleston, SC
Click here to add this to my saved trials
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Calgary,
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Calgary,
Click here to add this to my saved trials
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Status: Enrolling
Updated:  12/31/1969
Merz Investigational Site # 0010411
mi
from
Los Gatos, CA
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Status: Enrolling
Updated: 12/31/1969
Merz Investigational Site # 0010411
mi
from
Los Gatos, CA
Click here to add this to my saved trials
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Status: Enrolling
Updated:  12/31/1969
Merz Investigational Site #001281
mi
from
San Diego, CA
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Status: Enrolling
Updated: 12/31/1969
Merz Investigational Site #001281
mi
from
San Diego, CA
Click here to add this to my saved trials
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Status: Enrolling
Updated:  12/31/1969
Merz Investigative Site# 001272
mi
from
Austin, TX
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Status: Enrolling
Updated: 12/31/1969
Merz Investigative Site# 001272
mi
from
Austin, TX
Click here to add this to my saved trials
An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Enrolling
Updated:  12/31/1969
J&S Studies
mi
from
College Station, TX
An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea
Status: Enrolling
Updated: 12/31/1969
J&S Studies
mi
from
College Station, TX
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Encinitas, CA
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Encinitas, CA
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigator Site
mi
from
Redwood City, CA
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigator Site
mi
from
Redwood City, CA
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigator Site
mi
from
Washington,
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigator Site
mi
from
Washington,
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigator Site
mi
from
Boston, MA
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigator Site
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigator Site
mi
from
Clinton Township, MI
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigator Site
mi
from
Clinton Township, MI
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Warren, MI
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Warren, MI
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Fridley, MN
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Fridley, MN
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Omaha, NE
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
New York, NY
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigator Site
mi
from
Durham, NC
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigator Site
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigator Site
mi
from
Portland, OR
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigator Site
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Austin, TX
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
San Antonio, TX
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigator Site
mi
from
Laguna Hills, CA
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigator Site
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Miami, FL
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigator Site
mi
from
Minneapolis, MN
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigator Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigator Site
mi
from
Winston-Salem, NC
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigator Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Nashville, TN
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Fort Washington, PA
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Fort Washington, PA
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigator Site
mi
from
Boynton Beach, FL
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigator Site
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Knoxville, TN
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated:  12/31/1969
Shiley Eye Center
mi
from
La Jolla, CA
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated: 12/31/1969
Shiley Eye Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated:  12/31/1969
Gordon -Weiss Vision Institute
mi
from
San Diego, CA
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated: 12/31/1969
Gordon -Weiss Vision Institute
mi
from
San Diego, CA
Click here to add this to my saved trials
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated:  12/31/1969
Center for Excellence in Eye Care
mi
from
Miami, FL
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated: 12/31/1969
Center for Excellence in Eye Care
mi
from
Miami, FL
Click here to add this to my saved trials
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated:  12/31/1969
Price Vision Group
mi
from
Indianapolis, IN
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated: 12/31/1969
Price Vision Group
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated:  12/31/1969
Durrie Vision
mi
from
Kansas City, KA
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated: 12/31/1969
Durrie Vision
mi
from
Kansas City, KA
Click here to add this to my saved trials
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated:  12/31/1969
Wilmer Eye Institute, Johns Hopkins University
mi
from
Baltimore, MD
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated: 12/31/1969
Wilmer Eye Institute, Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated:  12/31/1969
Minnesota Eye Consultants, PA
mi
from
Minneapolis, MN
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated: 12/31/1969
Minnesota Eye Consultants, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated:  12/31/1969
Cornea & Laser Eye Institute; Hersh Vision Group
mi
from
Teaneck, NJ
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated: 12/31/1969
Cornea & Laser Eye Institute; Hersh Vision Group
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated:  12/31/1969
Edward Harkness Eye Institute-Columbia University Medical Center
mi
from
New York, NY
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated: 12/31/1969
Edward Harkness Eye Institute-Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated:  12/31/1969
Ophthalmic Consultants of Long Island
mi
from
Rockville Centre, NY
Corneal Collagen Cross-linking for Progressive Keratoconus
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
Status: Enrolling
Updated: 12/31/1969
Ophthalmic Consultants of Long Island
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne
Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences, Dermatology
mi
from
Winston-Salem, NC
Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne
Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences, Dermatology
mi
from
Winston-Salem, NC
Click here to add this to my saved trials